EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025.
Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET. Mr. Hughes will join the “Pros and Cons of Royalty Model – Especially in Current Financing Environment” panel discussion at 4:00 PM ET. Mr. Sitko will participate in the “Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?” panel at 5:00 PM ET. Registration for the conference can be accessed by visiting https://ct.to/wD4ms7s. XOMA Royalty’s presentations can be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.
In addition, members of XOMA Royalty’s business development team will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held on May 20, 2025, in New York, NY.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
XOMA Investor Contact Juliane Snowden XOMA Royalty +1 646-438-9754 This email address is being protected from spambots. You need JavaScript enabled to view it. | XOMA Media Contact Kathy Vincent KV Consulting & Management This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$24.19 |
Daily Change: | -0.25 -1.02 |
Daily Volume: | 7,278 |
Market Cap: | US$284.960M |
March 17, 2025 February 24, 2025 February 04, 2025 December 02, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load